Slingshot members are tracking this event:
Breakthrough Therapy Designation from U.S. FDA for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer
Slingshot Insights Explained
Oct 15, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Loxo-292, Thyroid Cancer